Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02166476 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
A Phase 3 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
NCT02166476 is a Phase 3 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 550 participants.
The verdict
NCT02166476, a Phase 3 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
Study Summary
Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
Interventions
- DRUG Saline
- DRUG Meropenem-Vaborbactam
- DRUG Levofloxacin
- DRUG Piperacillin-Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2014-11-20 |
| Est. Completion | 2016-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02166476
The ClinicalTrials.gov registry entry for NCT02166476 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT02166476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02166476 about?
NCT02166476 is a clinical study titled "Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP". Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
What is the current status of trial NCT02166476?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2014-11-20. Estimated completion is 2016-04-28.
What interventions are being tested in trial NCT02166476?
The interventions under investigation include: Saline (DRUG), Meropenem-Vaborbactam (DRUG), Levofloxacin (DRUG), Piperacillin-Tazobactam (DRUG).
Who is sponsoring clinical trial NCT02166476?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.